Mr. Donald McCaffrey reports

RESVERLOGIX ANNOUNCES ONE-YEAR EXTENSION OF DEBENTURE

Resverlogix Corp. has closed a one-year extension of the company's $6-million (U.S.) secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co. Ltd., and payment of accrued interest thereon, extending the maturity date to May 13, 2024. In connection with the extension, the interest rate was amended from 10 per cent to 12 per cent per annum, commencing on May 14, 2023.

"We are pleased that Hepalink has extended the debenture's maturity date by an additional year, illustrating their continued support of our partnership," stated Donald McCaffrey, president and chief executive officer of Resverlogix. "The steadfast commitment of our partners allows us to focus on our mutual goal of advancing apabetalone's clinical development, for the benefit of chronic disease patients. Over the past several months we have been working diligently with Hepalink in order to prepare for their involvement in our upcoming BETonMACE2 trial which has FDA breakthrough therapy designation."

About Resverlogix Corp.

Founded in 2001, Resverlogix is a Calgary-based, late-stage biotechnology company and the world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.

The company's new class of epigenetic therapies are designed to regulate the expression of disease-causing genes. Resverlogix aims to improve patients' lives by restoring biological functions -- altered by serious illnesses such as cardiovascular disease -- back to a healthier state.

The company's clinical program is focused on evaluating its lead candidate, apabetalone, for the treatment of cardiovascular disease and associated co-morbidities, and post-COVID-19 conditions.

Resverlogix has partnered with Eversana, the pioneer of next-generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

We seek Safe Harbor.